Background/aim: Ductal carcinoma in situ is considered a local disease with no metastatic
potential, thus sentinel lymph node biopsy (SLNB) may be deemed an overtreatment. SLNB …

Background Sentinel lymph node biopsy (SLNB) is unnecessarily performed too often,
owing to the high upstaging rates of ductal carcinoma in situ (DCIS). This study aimed to …

Background Nodal involvement in ductal carcinoma in situ (DCIS) is rare. In patients with
DCIS diagnosis prior to mastectomy, a sentinel lymph node biopsy (SLNB) is usually …

Background A substantial proportion of women with a pre-operative diagnosis of pure ductal
carcinoma in situ (DCIS) has a final diagnosis of invasive breast cancer (IBC) after surgical …

Introduction Ductal Carcinoma in Situ (DCIS) is a precursor lesion of Invasive Breast
Carcinoma (IBC), but we cannot predict which will progress to invasive disease. This study …

Simple Summary A diagnosis of ductal carcinoma in situ, made on biopsy, is often followed
by surgery or radiotherapy because of the risk of an upgrading disease upon subsequent …

Background The optimal axillary lymph node (ALN) management strategy in patients
diagnosed with ductal carcinoma in situ (DCIS) preoperatively remains controversial. The …

Purpose Ductal carcinoma in situ (DCIS)—preinvasive breast cancer—with lymph node
metastasis can clinically be treated as different stages: occult invasive cancer with true …

Background We conducted a prospective study with the intention to omit surgery for patients
with ductal carcinoma in situ (DCIS) of the breast. We aimed to identify clinicopathological …

Background There are few established indications for sentinel lymph node biopsy (SLNB) in
breast ductal carcinoma in situ (DCIS). This study examines factors contributing to the high …